Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
about
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncologyStructural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferaseStructural basis for resistance to diverse classes of NAMPT inhibitorsIdentification of novel Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors using computational approaches.Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells.Depletion of the central metabolite NAD leads to oncosis-mediated cell death.Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.Metabolic Response to NAD Depletion across Cell Lines Is Highly VariableSupplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactorCross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment.
P2860
Q26745678-393E7BAD-18BC-46EF-B772-32277DEEAE86Q27690154-07B77BA2-2DA8-4CAF-8FF3-00A17D536CD0Q28543568-873F15E0-5DDF-4405-9FA1-A27083E52AC0Q30152633-0EA6147B-1D0B-4576-87C9-043B048A108CQ33422176-67AABE6C-3730-40A3-A0C7-FE0FC5776485Q33844916-5672D4ED-A5D1-4C70-ABE5-4D2D6AC5FE08Q34737798-76D980C1-4B08-4A70-ABC5-D35D3FC6CE44Q35860727-7F26163C-C092-4499-B87E-B9DA3916B91AQ36155272-CCE1916C-7380-45EC-944D-C682A5986DEBQ37448050-9131B488-2C7F-4EC7-B9AD-B0DC638CFD46Q38736710-A981BF9C-978E-4649-9D5D-6FFCAC7E8FCBQ38836121-38852693-9164-493B-A9E5-F9C40A81D437Q38928592-EC8AED43-CFEC-4DAE-BAF7-619DCA9B744BQ41869171-37D3FF14-F59B-4230-903F-84AE4F928B11Q53694785-27D0C681-A86B-4B89-A4E7-15045ABA88B4
P2860
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Structure-based discovery of n ...... ransferase (nampt) inhibitors.
@en
Structure-based discovery of n ...... mide phosphoribosyltransferase
@nl
type
label
Structure-based discovery of n ...... ransferase (nampt) inhibitors.
@en
Structure-based discovery of n ...... mide phosphoribosyltransferase
@nl
prefLabel
Structure-based discovery of n ...... ransferase (nampt) inhibitors.
@en
Structure-based discovery of n ...... mide phosphoribosyltransferase
@nl
P2093
P356
P1476
Structure-based discovery of n ...... transferase (nampt) inhibitors
@en
P2093
Alexandre J Buckmelter
Bianca M Liederer
Bingsong Han
Chase C Smith
Dominic J Reynolds
Geeta Sharma
Guiling Zhao
Janet Gunzner-Toste
P304
P356
10.1021/JM4008664
P407
P577
2013-07-31T00:00:00Z